EUnetHTA is extended for one year and focuses on COVID-19

9 July 2020 - The European project EUnetHTA, in which TLV, SBU and the Swedish Medicines Agency are Swedish partners, ...

Read more →

TLV is reviewing the subsidy of SGLT-2 inhibitors

8 July 2020 - TLV has started a review of subsidy restrictions for the SGLT-2 inhibitors. ...

Read more →

FINOSE - Nordic cooperation extended to promote patients' access to medicines

30 June 2020 - The latest FINOSE report is used as the basis of all the five Nordic countries in ...

Read more →

Health economic assessment of Ondexxya in life-threatening or uncontrolled bleeding

26 June 2020 - TLV has developed a health economic assessment for the regions of the drug Ondexxya (andexanet alfa).  ...

Read more →

Health economic assessment of Waylivra in familial chylomicronaemia

11 June 2020 - TLV has made a health economic assessment to the regions of the drug Waylivra (volansorsen).  ...

Read more →

Desloratadine new exchange groups

9 June 2020 - As of 1 July, desloratadine will be included as exchange group on the list of products ...

Read more →

Health economic assessment of Polivy in combination with bendamustine and rituximab

5 June 2020 - The treatment is intended for adult patients with diffuse large-cell B-cell lymphomas who relapse or do not ...

Read more →

Health economic assessment of Vimizim in mucopolysaccharidosis type IVA (Morquio A syndrome)

29 May 2020 - TLV has developed a health economic knowledge base for the regions of the drug Vimizim (elosulfase alfa) ...

Read more →

TLV has decided to reconsider the subsidy status for certain drugs

26 May 2020 - TLV initiates a review for review of subsidy status for drugs that are part of one ...

Read more →

Health economic assessment of Bavencio and Inlyta

18 May 2020 - TLV has developed a health economic assessment for the regions regarding the combination of avelumab (Bavencio) and ...

Read more →

Health economic assessment of Spravato in treatment resistant depression

14 May 2020 - TLV has developed a health economic knowledge base for the regions for Spravato (esketamine).  ...

Read more →

Third evaluation within the FINOSE collaboration

12 May 2020 - Together with the corresponding authorities in Finland and Norway, TLV has produced a joint evaluation report ...

Read more →

Health economic assessment of gene therapy Zynteglo in transfusion-dependent beta-thalassemia

11 May 2020 - TLV has developed a health-economic knowledge base for the Zynteglo gene therapy (autologous CD34-positive cells expressing the ...

Read more →

HyQvia gets a higher price

8 May 2020 - HyQvia 100 mg/mL solution for injection contains human immunoglobulin, which is an antibody used to strengthen ...

Read more →

Health economic assessment of Keytruda in head and neck cancer

29 April 2020 - TLV has developed a health economic knowledge base for the regions of the drug Keytruda (pembrolizumab).  ...

Read more →